KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $42.1 million.

  • Adaptive Biotechnologies' Other Operating Expenses rose 1228.74% to $42.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.5 million, marking a year-over-year decrease of 1392.48%. This contributed to the annual value of $165.7 million for FY2024, which is 1333.94% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Other Operating Expenses is $42.1 million, which was up 1228.74% from $42.0 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Other Operating Expenses high stood at $67.4 million for Q4 2023, and its period low was $31.0 million during Q1 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $40.3 million (2023), whereas its average is $41.1 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 8881.41% in 2021, then tumbled by 4056.4% in 2024.
  • Adaptive Biotechnologies' Other Operating Expenses (Quarter) stood at $41.5 million in 2021, then dropped by 1.8% to $40.7 million in 2022, then skyrocketed by 65.41% to $67.4 million in 2023, then crashed by 40.56% to $40.0 million in 2024, then grew by 5.01% to $42.1 million in 2025.
  • Its Other Operating Expenses stands at $42.1 million for Q3 2025, versus $42.0 million for Q2 2025 and $40.4 million for Q1 2025.